Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971446 · ClinicalTrials.gov registry record
Healthy Little Eyes
A clinical trial of Hypoxic Ischemic Encephalopathy and Encephalopathy, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT05971446: Recruiting study of Hypoxic Ischemic Encephalopathy and Encephalopathy, sponsored by University of Wisconsin, Madison.
NCT05971446 is a study of Hypoxic Ischemic Encephalopathy and Encephalopathy that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 125 participants, above the 73-participant average among 13 other Hypoxic Ischemic Encephalopathy trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05971446, a study of Hypoxic Ischemic Encephalopathy and Encephalopathy, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to gather more information on how eye injury is related to a baby's future development and see if eye function and brain test results can be used, along with current measures, to better diagnose and treat babies with hypoxic-ischemic encephalopathy (HIE). Participants will undergo up to two eye exam sessions, involving both Visual Evoked Potential (VEP) and Electroretinogram (ERG) exams.
Primary Outcome
The least absolute shrinkage and selection operator technique will be utilized to determine whether ERG measures predict neurodevelopmental outcomes
Conditions Studied
Interventions
- DEVICE Visual Evoked Potential (VEP)
- DEVICE Electroretinogram (ERG)
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2029-07 |
What NCT05971446 shows while recruiting
NCT05971446 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, above the 73-participant average among 13 other Hypoxic Ischemic Encephalopathy trials with a reported enrollment target (71% higher).
The record links to 3 conditions, with Hypoxic Ischemic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Visual Evoked Potential (VEP) is the first listed.
NCT05971446 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05971446 about?
NCT05971446 is a clinical study titled "Healthy Little Eyes". The purpose of this research study is to gather more information on how eye injury is related to a baby's future development and see if eye function and brain test results can be used, along with current measures, to better diagnose and treat babies with hypoxic-ischemic encephalopathy (HIE). Parti...
What is the current status of trial NCT05971446?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2020-02-24. Estimated completion is 2029-07.
What conditions does trial NCT05971446 study?
This clinical trial studies the following conditions: Hypoxic Ischemic Encephalopathy, Encephalopathy, Neonatal Encephalopathy.
What interventions are being tested in trial NCT05971446?
The interventions under investigation include: Visual Evoked Potential (VEP) (DEVICE), Electroretinogram (ERG) (DEVICE).
Who is sponsoring clinical trial NCT05971446?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05971446 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoxic Ischemic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05971446's enrollment target sits among peer trials
125 4th of 13 higher than 10 of 13 other Hypoxic Ischemic Encephalopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoxic Ischemic Encephalopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The HIEnome Study: Genome Sequencing for Perinatal HIE
RECRUITING · NA
-
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
RECRUITING · Early Phase 1
-
Dose Optimization of Caffeine for HIE
RECRUITING · Phase 1
-
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
RECRUITING · NA
-
Systemic Biomarkers of Brain Injury From Hyperammonemia
RECRUITING
-
Spinal Stimulation and Mobility Devices
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI